An Investor Consortium consisting of funds managed by ECM Equity Capital Management GmbH (“ECM”), PINOVA Capital GmbH (“PINOVA”) and Gilde Healthcare (“Gilde Healthcare Private Equity”) (together the “Investor Consortium”) has acquired a majority stake in DETAX Group, the leading supplier of polymer materials for medical applications, in the context of a management buy-out. The two long-term managing directors, Mrs. Ursula Juretzki-Mangold and Mr. Ralf König, have invested alongside the Investor Consortium as part of the transaction.
DETAX, based in Ettlingen, Germany, was founded in 1953 and today employs approx. 110 people. As a specialist in polymer materials, the group offers its customers a comprehensive product portfolio of dental and otoplastic consumables. The group serves an international, broadly diversified and loyal customer base. End users of the products include dental practices, dental laboratories as well as audiologists and audio laboratories. The group operates in a non-cyclical, highly regulated market environment. Complying with such regulation, DETAX holds all relevant MDR certificates. This makes DETAX one of the first companies in the industry with an extensive MDR-certified product portfolio.
CODEX Partners prepared the commercial due diligence of the DETAX Group for the Investor Consortium. CODEX Partners advises investors on Commercial Due Diligence and Vendor Due Diligence, strategy development, cost optimization and restructuring of portfolio companies and in the development of industry platforms. Investors benefit from our experience from over 500 projects.